Ketamine clinical trials at University of California Health

7 in progress, 3 open to eligible people

Showing trials for

  • Ketamine on Intraoperative Motor Evoked Potentials

    open to eligible people ages 18-100

    The goal of this clinical trial is to learn about the effect of ketamine on intraoperative motor evoked potentials in adult patients undergoing thoracolumbar spinal fusions. Participants will undergo a standard anesthetic. In addition to the standard anesthetic, the patients will be administered increasing doses of ketamine with motor-evoked potentials being measured at each dose, to assess any impacts.

    at UCSF

  • Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

    open to eligible people ages 18-69

    The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: - Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? - Is IM ketamine safe and tolerable among patients with MeUD? Participants will: - Receive 3 monitored doses of IM ketamine - Have 3 preparation and 4 integration psychotherapy visits - Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention

    at UCSF

  • Pragmatic Trial of Psilocybin Therapy in Palliative Care

    open to eligible people ages 18 years and up

    This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).

    at UCLA UCSF

  • Ketamine Effects on Learning in Eating Disorders

    Sorry, not yet accepting patients

    This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.

    at UCSF

  • Ketamine for Veterans With Parkinson's Disease

    Sorry, not yet accepting patients

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.

    at UCSF

  • Morphine or Ketamine for Analgesia

    Sorry, not yet accepting patients

    Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.

    at UC Davis

  • Induction Medications Used in the Trauma RSI

    Sorry, not yet accepting patients

    To compare the outcomes of the use of propofol, etomidate, and ketamine as induction agents for adult trauma patients undergoing intubation within 24 hours of admission. The primary goal is to determine the ideal agent that should be used in this patient population for intubations.

    at UC Irvine

Our lead scientists for Ketamine research studies include .

Last updated: